Polypodium leucotomos extract: A status report on clinical efficacy and safety

Journal of Drugs in Dermatology

Volumn 14, Issue 3, 2015, Pages 254-259

  Winkelmann, Richard R ^a   Del Rosso, James ^b   Rigel, Darrell S ^c  

^a Rigel Dermatology Group   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPODIUM LEUCOTOMOS EXTRACT; DERMATOLOGICAL AGENT; PLANT EXTRACT;

ACUTE TOXICITY; AMES TEST; ARTICLE; ATOPIC DERMATITIS; BLOATING; CARCINOGENICITY; CHRONIC TOXICITY; COGNITIVE DEFECT; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; IN VIVO STUDY; LOTION; MUTAGENICITY; NONHUMAN; PATIENT; PRURITUS; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASES; ISOLATION AND PURIFICATION; POLYPODIUM; PROCEDURES; SKIN DISEASES; TREATMENT OUTCOME;

DERMATOLOGIC AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PLANT EXTRACTS; POLYPODIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84924650170     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Horvath A, Alvarado F, Szocs J, et al. Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature 1967;214:1256-1258.\
2. Gomes AJ, Lunardi CN, Gonzalez S, et al. The antioxidant action of Polypodium leucotomos extract and kojic acid: reactions with reactive oxygen species. Braz J Med Biol Res 2001;34:1487-94.
3. Gonzalez S, Pathak MA. Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin photosensitization by Polypodium leucotomos. Photodermatol Photoimmunol Photomed. 1996;12:45-56.
4. Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad Dermatol. 2004;50(1):41-9.
5. Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004;51(6):910-8.
6. Philips N, Smith J, Keller T, et al. Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and matrixmetalloproteinase-1 in ultraviolet radiation exposed fibroblasts, and keratinocytes. J Dermatol Sci. 2003;32:1-9.
7. Philips N, Dulaj l, upadhya T. Cancer cell growth and extracellular matrix remodeling mechanism of ascorbate; beneficial modulation by P. leucotomos. Anticancer Res. 2009;29:3233-3238.
8. Zattra E, Coleman C, Arad S, et al. Oral Polypodium leucotomos decrease-sUV- induced Cox-2 expression, inflammation, and enhances DNA repair in Xpc mice. Am J Pathol. 2009;175:1952-61.
9. Preston BD, Doshi R. Molecular targets of chemical mutagens. Adv Exp Med Biol. 1991;283: 193-209.
10. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet lightinduced skin carcinogenesis. Mol Carcinog. 1999;25:231-40.
11. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 1999; 20:1939-44.
12. Rundhaug JE, Pavone A, Kim E, et al. The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent. Mol Carcinog. 2007;46: 981-92.
13. Spanish Ministry of Health. Polypodium leucotomos extract (Difur) in the treatment of psoriasis and atopic dermatitis. Assigned Registration # 55, 757. January 5, 1982.
14. Padilla HC, Laínez H, Pacheco JA. A new agent (hydrophilic fraction of polypodium leucotomos) for management of psoriasis. Int J Dermatol. 1974;13(5):276-82.
15. Del Pino G, De Sambricio GF, Colomo GC. Comparative study between 120 mg anapsos and a placebo in 37 psoriasis patients. Med Cutan Ibero Lat Am. 1982;10(3):203-8.
16. Alvarez BP. 2 years personal experience in anapsos treatment of psoriasis in various clinical forms. Med Cutan Ibero La Am. 1983;11(1):65-72.
17. Jimenez D, Doblare E, Naranjo R, et al. Anapsos, an antipsoriatic drug, in atopic dermatitis. Allergol Immunopathol. 1987;15(4):185-9.
18. González S, Pathak MA, Cuevas J, et al. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed. 1997;13(1-2):50-60.
19. Alvarez XA, Pichel V, Perez P. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Methods Find Exp Clin Pharmacol. 2000; 22(7):585-94.
20. Reyes E, Jaén P, de las Heras E, et al. Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo: A pilot study. J Dermatol Sci. 2006;41(3):213-6.
21. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21(7):942-50.
22. Caccialanza M, Percivalle S, Piccinno R, et al. Photoprotective activity of oral polypodium leucotomos extract in 25 patients with idiopathic photodermatoses. Photodermatol Photoimmunol Photomed. 2007;23(1):46-7.
23. Villa A, Viera MH, Amini S. Decrease of ultraviolet A light-induced "common deletion" in healthy volunteers after oral Polypodium leucotomos extract supplement in a randomized clinical trial. J Am Acad Dermatol. 2010;62(3):511-3.
24. Caccialanza M1, Recalcati S, Piccinno R. Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses. G Ital Dermatol Venereol. 2011;146(2):85-7.
25. Ramírez-Bosca A1, Zapater P, Betlloch I Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial. Actas Dermosifiliogr. 2012;103(7):599-607.
26. Tanew A1, Radakovic S, Gonzalez S, Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption. J Am Acad Dermatol. 2012;66(1):58-62.
27. Solivellas BM1, Martín TC. Polypodium leucotomos Extract use to prevent and reduce the risk of infectious diseases in high performance athletes. Infect Drug Resist. 2012;5:149-53.
28. Aguilera P1, Carrera C, Puig-Butille JA et al. Benefits of oral Polypodium Leucotomos extract in MM high-risk patients. J Eur Acad Dermatol Venereol. 2013;27(9):1095-100.
29. Ahmed AM1, Lopez I, Perese F. A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. JAMA Dermatol. 2013;149(8):981-3.
30. Nestor MS, Berman B. A safety and efficacy study of oral heliocare. Poster presented at Practical Dermatology and Dermatopathology Symposium, Vail, CO. August 16, 2014.